| PRECLINICAL | evidence | The non-muscle actinopathy-associated mutation E334Q in cytoskeletal gamma-actin perturbs interaction of actin filaments with myosin and ADF/cofilin family proteins. | Thymosin β4 | — | 2024-03-06 |
| PRECLINICAL | evidence | Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. | TB 500 | Wound healing | 2024-03-01 |
| PRECLINICAL | evidence | A top-down proteomic approach reveals a salivary protein profile able to classify Parkinson's disease with respect to Alzheimer's disease patients and to healthy controls. | Thymosin β4 | — | 2024-02-01 |
| PRECLINICAL | evidence | Thymosin beta4 Regulates the Differentiation of Thymocytes by Controlling the Cytoskeletal Rearrangement and Mitochondrial Transfer of Thymus Epithelial Cells. | Tbeta4 | — | 2024-01-16 |
| PRECLINICAL | evidence | Th22 is the effector cell of thymosin beta15-induced hair regeneration in mice. | Tbeta4 | — | 2024-01-08 |
| PRECLINICAL | evidence | Thymosin beta4 improves the survival of cutaneous flaps of rats and activates the Wnt/beta-catenin pathway. | Thymosin β4 | — | 2024-01-01 |
| PRECLINICAL | evidence | The fascinating theory of fetal programming of adult diseases: A review of the fundamentals of the Barker hypothesis. | Thymosin beta 4 | — | 2024-01-01 |
| PRECLINICAL | evidence | Therapeutic applications of thymosin peptides: a patent landscape 2018-present. | Thymosin β4 | — | 2023-12-01 |
| PRECLINICAL | evidence | A Novel Combination Therapy Tbeta4/VIP Protects against Hyperglycemia-Induced Changes in Human Corneal Epithelial Cells. | Tbeta4 | Glycemic control · preclinical | 2023-11-07 |
| PRECLINICAL | evidence | Proteomic analysis of salivary inflammatory biomarkers of developmental gingival enlargements in patients with West and Noonan syndromes: a preliminary pilot single-center retrospective study. | Thymosin β4 | — | 2023-11-01 |
| PRECLINICAL | evidence | Detection and quantification of the metabolite Ac-Tbeta(1-14) in in vitro experiments and urine of rats treated with Ac-Tbeta4: A potential biomarker of Ac-Tbeta4 for doping tests. | Tbeta4 | — | 2023-11-01 |
| PRECLINICAL | evidence | TMSB4X: A novel prognostic marker for non-small cell lung cancer. | Thymosin beta 4 | — | 2023-11-01 |
| PRECLINICAL | evidence | Therapeutic Effect of Prolyl Endopeptidase Inhibitor in High-fat Diet-induced Metabolic Dysfunction-associated Fatty Liver Disease. | Thymosin β4 | — | 2023-10-28 |
| PRECLINICAL | evidence | Effect of thymosin beta4 on lipopolysaccharide‑stimulated brain microvascular endothelial cell remodeling: A possible role in blood‑brain barrier injury. | Tbeta4 | — | 2023-10-01 |
| PRECLINICAL | evidence | Bioinspired Platelet-Anchored Electrospun Meshes for Tight Inflammation Manipulation and Chronic Diabetic Wound Healing. | Tbeta4 | — | 2023-10-01 |
| PRECLINICAL | evidence | Deficiency of endothelial sirtuin1 in mice stimulates skeletal muscle insulin sensitivity by modifying the secretome. | Tbeta4 | — | 2023-09-11 |
| PRECLINICAL | evidence | Hypermethylation of thymosin beta4 predicts a poor prognosis for patients with acute-on-chronic hepatitis B liver failure. | Tbeta4 | — | 2023-08-01 |
| PRECLINICAL | evidence | Proteins from toad's parotoid macroglands: do they play a role in gland functioning and chemical defence? | Thymosin beta 4 | — | 2023-06-16 |
| PRECLINICAL | evidence | Thymosin Beta 4 Protects Hippocampal Neuronal Cells against PrP (106-126) via Neurotrophic Factor Signaling. | Tbeta4 | — | 2023-05-06 |
| PRECLINICAL | evidence | Purification of human beta- and gamma-actin from budding yeast. | Tbeta4 | — | 2023-05-01 |
| PRECLINICAL | evidence | Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis. | Tbeta4 | Skin appearance & aging | 2023-05-01 |
| PRECLINICAL | evidence | The Pathophysiological Role of Thymosin beta4 in the Kidney Glomerulus. | Tbeta4 | Kidney function | 2023-04-22 |
| PRECLINICAL | evidence | The preliminary study of exosomes derived from thymosin beta 4-treated adipose-derived stem cells in fat grafting. | Tbeta4 | Weight & fat loss · preclinical | 2023-04-01 |
| PRECLINICAL | evidence | Thymosin beta4, a potential marker of malignancy and prognosis in hepatocellular carcinoma. | Tbeta4 | — | 2023-04-01 |
| PRECLINICAL | evidence | Thymosins in health & disease, the sixth international symposium. | Thymosin b4 | — | 2023-04-01 |
| PRECLINICAL | evidence | TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs. | TB500 | — | 2023-04-01 |
| PRECLINICAL | evidence | Cell starvation increases uptake of extracellular Thymosin beta4 and its complexes with calcium. | Thymosin beta 4 | — | 2023-03-01 |
| PRECLINICAL | evidence | Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. | TB4 | Longevity & cellular aging | 2023-03-01 |
| PRECLINICAL | evidence | Provocative non-canonical roles of p53 and AKT signaling: A role for Thymosin beta4 in medulloblastoma. | Thymosin beta 4 | — | 2023-03-01 |
| PRECLINICAL | evidence | Thymosin beta-4 - A potential tool in healing middle ear lesions in adult mammals. | TB4 | — | 2023-03-01 |
| PRECLINICAL | evidence | Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. | Thymosin beta 4 | — | 2023-03-01 |
| PRECLINICAL | evidence | Thymosin beta-4 - A potential tool in healing middle ear lesions in adult mammals. | Thymosin beta 4 | — | 2023-03-01 |
| PRECLINICAL | evidence | [Review on biological effects and mechanism of Ac-SDKP]. | Thymosin β4 | — | 2023-02-20 |
| PRECLINICAL | evidence | Novel Biotherapeutics Targeting Biomolecular and Cellular Approaches in Diabetic Wound Healing. | Thymosin beta 4 | — | 2023-02-18 |
| PRECLINICAL | evidence | Exogenous Thymosin Beta 4 Suppresses IPF-Lung Cancer in Mice: Possibly Associated with Its Inhibitory Effect on the JAK2/STAT3 Signaling Pathway. | Tbeta4 | — | 2023-02-14 |
| PRECLINICAL | evidence | Thymosin Beta 4 Inhibits LPS and ATP-Induced Hepatic Stellate Cells via the Regulation of Multiple Signaling Pathways. | Tbeta4 | — | 2023-02-08 |
| PRECLINICAL | evidence | Hypomethylation of thymosin beta4 promoter is associated with glucocorticoid therapy in patients with acute-on-chronic hepatitis B-induced liver failure. | Tbeta4 | — | 2023-01-03 |
| PRECLINICAL | evidence | Bioactive fibrous scaffolds with programmable release of polypeptides regulate inflammation and extracellular matrix remodeling. | Tbeta4 | — | 2023-01-01 |
| PRECLINICAL | evidence | Exploring cell surface markers and cell-cell interactions of human breast milk stem cells. | Tbeta4 | — | 2023-01-01 |
| PRECLINICAL | evidence | Antioxioxidant and antiapoptotic effects of Thymosin beta4 in Abeta-induced SH-SY5Y cells via the 5-HTR1A/ERK axis. | Tbeta4 | preclinical | 2023-01-01 |
| PRECLINICAL | evidence | Thymosin beta4 and Actin: Binding Modes, Biological Functions and Clinical Applications. | Tbeta4 | Wound healing | 2023-01-01 |
| PRECLINICAL | evidence | Neurotrophic keratopathy: current challenges and future prospects. | Thymosin β4 | Eye & vision health | 2022-12-01 |
| PRECLINICAL | evidence | Proteomic characterisation of prostate cancer intercellular communication reveals cell type-selective signalling and TMSB4X-dependent fibroblast reprogramming. | Thymosin beta 4 | Skin appearance & aging · preclinical | 2022-12-01 |
| PRECLINICAL | evidence | Nuclear factor (erythroid-derived 2)-like 2 counter-regulates thymosin beta-4 expression and primary cilium formation for HeLa cervical cancer cell survival. | TB4 | — | 2022-11-23 |
| PRECLINICAL | evidence | Nuclear factor (erythroid-derived 2)-like 2 counter-regulates thymosin beta-4 expression and primary cilium formation for HeLa cervical cancer cell survival. | Thymosin beta 4 | — | 2022-11-23 |
| PRECLINICAL | evidence | HeLa Cervical Cancer Cells Are Maintained by Nephronophthisis 3-Associated Primary Cilium Formation via ROS-Induced ERK and HIF-1alpha Activation under Serum-Deprived Normoxic Condition. | Thymosin β4 | — | 2022-11-22 |
| PRECLINICAL | evidence | The Role of Tbeta4-POP-Ac-SDKP Axis in Organ Fibrosis. | Tbeta4 | Liver health | 2022-10-31 |
| PRECLINICAL | evidence | Aberrant Expression of Thymosin Beta-4 Correlates With Advanced Disease and BRAF V600E Mutation in Thyroid Cancer. | Thymosin beta 4 | — | 2022-10-01 |
| PRECLINICAL | evidence | Multi-analyte screening of small peptides by alkaline pre-activated solid phase extraction coupled with liquid chromatography-high resolution mass spectrometry in doping controls. | TB500 | — | 2022-08-02 |
| PRECLINICAL | evidence | Platelets and osteoblasts: secretome connections. | Thymosin β4 | — | 2022-08-01 |